Convalescent Plasma Fact Sheets and Toolkit for Health Professionals
The U.S. Food and Drug Administration continues to play a critical role in accelerating medical countermeasures to treat and prevent COVID-19. FDA is facilitating the development of numerous potential COVID-19 treatments. Working together with health care organizations and other partners across the U.S., FDA is committed to slowing the spread and meeting the challenge of COVID-19. Below are some useful resources:
Convalescent Plasma Factsheet
(English - PDF, 379KB)
The factsheet provides an overview of key information about convalescent plasma to help stakeholders address questions about convalescent plasma.
Convalescent Plasma EUA Fact Sheet for Health Care Providers
(English - PDF, 192KB)
The EUA fact sheet to healthcare providers outlines information on the Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product COVID-19 convalescent plasma to treat hospitalized patients with COVID-19.
Convalescent Plasma Fact Sheet for Patients and Caregivers
This fact sheet contains information to help patients understand the risks and benefits of taking the COVID-19 convalescent plasma.
Convalescent Plasma Tweets
(English - PDF, 267KB)
Click on the links above for a series of connected Tweets (twitter thread) and accompanying images that will help provide additional context for messaging.